Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Biotechnology
- Diagnostic
- Therapeutic
- Antibody
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27461
License Grant
The agreement is to manufacture developmental, clinical and commercial quantities of anti-CD30 monoclonal antibody, which is a component of ADCETRIS. As part of the agreement the Licensor hereby grants an irrevocable, worldwide, nonexclusive license with the right to grant sublicenses, to each Licensor Invention which has been incorporated into the manufacturing process of the Bulk Drug Substance.
License Property
ADCETRIS®, or brentuximab vedotin, is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Licensee's proprietary technology.
The treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.
Field of Use
The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
IPSCIO Record ID: 4092
License Grant
Whereas, Licensor and Licensee wish to amend the Agreement as set forth in this Amendment. (Royalty amounts amended.) Licensor is the sole owner of the technology identified as an anti-CD3O antibody known as C1O.
License Property
The rights amended apply to the Royalty amounts that relate to an anti-CD30 antibody known as C10.
The anti-CD30 monoclonal antibody is the basis for the antibody component of ADCETRIS.
Field of Use
Adcetris is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).
IPSCIO Record ID: 4091
License Grant
Licensor hereby grants to Licensee an exclusive license in the Territory for the Field of Use, with the right to sublicense, to the Technology and Know-how and under any Patent Rights, to research, develop, make, have made for its own use and sale, use, import, export, sell or offer to sell the Product and to practice the method of any invention claimed in the Patent Rights.
License Property
Licensor is the sole owner of the technology identified as an anti-CD3O antibody known as C1O and, Licensee desires to acquire an exclusive license in the Territory for all uses in human and animal diagnostics and therapeutics with the right to sublicense, for the purposes of making, having made for its own use and sale, using and selling products and practicing any invention disclosed and claimed in the Patent Rights. In consideration for payment of royalties, Licensor hereby grants to Licensee an exclusive license in the Territory for the Field of Use, with the right to sublicense, to the Technology and Know-how and under any Patent Rights, to research, develop, make, have made for its own use and sale, use, import, export, sell or offer to sell the Product and to practice the method of any invention claimed in the Patent Rights. Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor; all expenses of obtaining and maintaining said patents shall be paid by Licensee. Licensor retains the right to practice such invention for its own internal research use. Licensor agrees to provide the hamster anti-mouse CD3O hybridoma and protein to Licensee promptly after the Effective Date for Licensee's own research use only. Licensee shall have the right to grant sublicenses to the Technology, Know-how and Patent Rights without the prior approval of Licensor. The license granted by this Agreement shall be Exclusive in the Licensed Field of Use for a term commencing as of the effective date of this Agreement and ending on the date ten (10) years from the date of first commercial sale of a Product(s) by Licensee; Licensee agrees to promptly inform Licensor in writing of the date of first commercial sale.
Product shall mean any product or part thereof which contains, is derived from or is developed using the Technology. 1.5 Technology shall mean the anti-CD3O antibody known as C-10.
The anti-CD30 monoclonal antibody is the basis for the antibody component of ADCETRIS.
Field of Use
Adcetris is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).
IPSCIO Record ID: 240612
License Grant
This amendment details terms, clarifies transfers of technology and modifies the royalty. The original agreement is exclusive.
License Property
The licensed property is regarding Licensors antibody-drug conjugate technology.
'ADCs utilize the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells. ADC technology employs synthetic, highly potent drugs that can be attached to antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.
Field of Use
The Field, described in the original agreement, means any and all Antibody targeting applications for human or animal use unless mutually agreed to by the Parties.
IPSCIO Record ID: 3285
License Grant
Licensor grants exclusive rights to develop, commercialize and market Rituxan outside the United States and Canada.
License Property
Rituximabis a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Field of Use
RITUXAN® (Rituximab) is indicated for the treatment of
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy
IPSCIO Record ID: 307594
License Grant
The parties partnered to jointly develop and commercialize three of Licensor’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
License Property
Epcoritamab (DuoBody-CD3xCD20) is a bispecific antibody created using Licensor’s proprietary DuoBody technology. Epcoritamab is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). In a number of laboratory models, epcoritamab has shown highly effective killing of CD20+ tumors and induced potent tumor cell lysis across a panel of B cell tumor lines. Epcoritamab is currently evaluated in a Phase 1/2 study for multiple hematological B cell malignancies.
The companies will partner to develop Licensor’s next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensor’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licensee’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensor’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licensee’s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.
Field of Use
The field of use is for the treatment of cancer utilizing antibodies. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.
Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
